Cell dose is a major criterion for cord blood unit (CBU) selection for allogeneic stem cell transplantation (allo-SCT). The aim of this study was the characterization of CBU cellular composition after thaw, and comparison with corresponding values at cryopreservation as reported by cord blood (CB) banks. The study included 87 CBUs, that were thawed for infusion in the context of single (n¼3) or dual-unit (n¼42) allo-SCT in adults with hematologic malignancies, from 8/2006 to 6/2013. Upon thawing, the cryoprotective solution (DMSO 10%) was either removed by centrifugation/washing (38 CBUs) or diluted in a less hypertonic solution of Dextran 40/Human Albumin 2.5% (49 CBUs). Total nucleated cells (TNC) were measured with a hematology analyzer, while enumeration of CD34+ stem cells was performed by singleplatform flow cytometry, according to ISHAGE guidelines. In 49 units, TNC and CD34+ cell viability was evaluated by addition of 7-AAD dye and sequential Boolean gating strategy. TNC counts after thawing were lower compared to their values at freezing (Wilcoxon test, p <10 -4 ), and the difference was more pronounced in the units that were washed prior to infusion (Tables 1 and 2 ). Total cell viability was low (mean value, 42.6%), but this was mainly due to neutrophils. Regarding CD34+ cells, there was a significant difference between absolute counts at cryopreservation and at thaw (p<10 -4 ). Despite reduction postthaw, the counts of both TNC and CD34+ cells did correlate with the corresponding values at cryopreservation by Spearman's analysis. Of note, washing seemed slightly advantageous in terms of CD34+ recovery (Tables 1 and 2 ). CD34+ cells retained high viability after thaw, with 90% of CBUs (44 out of 49 tested) demonstrating CD34+ viability !80%. Viability of <50% was noticed in only one CBU that failed to engraft.
In conclusion, CB cellular content and especially the CD34+ cell count is frequently shown to be inferior at thaw compared to cryopreservation. This probably reflects both the lack of standardization of CD34+ cell measurement and the effect of thawing procedure. Therefore, CD34+ cell viability may be a more meaningful marker for determining CBU quality. GVHD) is not yet defined. We examined the clinical courses of patients with SR-GVHD treated with Alemtuzumab. Methods: SR-GVHD was defined as progression with 3 days of 2 mg/kg of steroids, incomplete response in 7 days or inability to taper steroids by 14 days. Of 211 consecutive hematopoietic cell transplantation (HCT) recipients between April 2011 and May 2013, 34 (16%) recipients developed SR-GVHD and received Alemtuzumab (30mg subcutaneously every 14 days until progression or severe infectious complications for a maximum of 5 doses. Overall responses (OR) were evaluated by day 28 and 56 after administration of Alemtuzumab (McMillan et al, 2002) . Results: Median time to onset of acute GVHD was 25 days (range 7-127) post-HCT. All patients received systemic steroids first line and were defined as SR-GVHD. Median time from steroid initiation to Alemtuzumab therapy was 12 days (range 5-46). A median of 3 doses was given (range 1-4). Twenty seven patients (80%) were alive and evaluable for response by day 28 with 48% OR in 13 patients (8 CR and 5 PR), while 14 (52%) did not respond by day 28. Twenty patients (60%) were alive and evaluable for response by day 56 among whom 45% OR was noted (8 CR and 1 PR). No additional responses were observed after day 28 if not responded within the first 2 doses.
Median overall survival (OS) was 125.5 days (range 74-328). The group responding to Alemtuzumab by day 28 showed a longer duration of OS (median 156 days) compared to the non-responders by day 28 (median 99 days; p¼0.03). However, all but one patient died of infection (n¼10), GVHD (n¼16), GVHD and infection (n¼6) or other (n¼1). Infectious events were noted in all 34 patients, with 117 events including bacterial (n¼65 in 33 patients), viral (n¼44 in 28 patients) and fungal infections (n¼8 in 8 patients). Even in the patients responding to Alemtuzumab by day 28, there was one long-term survivor who is still alive at 310 days at last follow-up Conclusion: Response to Alemtuzumab seems to be an indicator for prolonged OS duration in patients with SR-GVHD although an improvement of 57 days is of questionable clinical significance given the morbidity associated with this therapy. However, Alemtuzumab therapy does not improve OS primarily because of high rate of infectious complication. Better supportive care is needed to improve outcome from infections after Alemtuzumab therapy for SR-GVHD. Introduction: Graft-versus-host disease (GvHD) is a major cause of mortality in allogeneic stem cell transplantation (ASCT). This study assessed the distribution and concordance of GvHD in upper and lower gastrointestinal (GI) biopsies and its correlation with CMV infection and extra-intestinal manifestations of GvHD. Methods: We performed a review of records from patients that had undergone ASCT from 2005 to 2013 in our institution and had GI GvHD diagnosis by histological samples from upper and/or lower endoscopy. We also evaluate presence of extra-intestinal manifestations of GvHD at the time of biopsy and CMV infection on histological and blood samples. Results: One hundred and eighty nine patients had performed ASCT during this period. Twenty eight patients (14.8%) had upper and/or lower acute GvHD diagnosis confirmed by biopsy. Extra-intestinal manifestation of GVHD was: skin in 19 (67.9%) and liver in 6 (21.4%) patients. Five (17.9%) had the 3 organ involvement. The GI GvHD staging was: I in 7 (25%), II in 4 (14.3%), III in 9 (32.1%) and IV in 8 (28.6%) patients.
The frequency and correlation between involvement of different parts of GI-GVHD are presented in Tables 1, 2 and 3. Nine (32.1%) had a positive blood sample for CMV and 5 (17.9%) had a histological sample (one in stomach, 3 in colon and one in rectum). Only one patient had both positive samples. There is no association between GI-GVHD staging and CMV infection on blood (p¼0.885) and on biopsy (p¼ 0.859).
The median follow up was 7.2 (1.8-90.6) month. Overall survival was 40% in 60 months and patients with stage IV GVHD had a less survival ( P¼ 0.004). Conclusion: Because sigmoid tract was the most frequent site of lower GI-GVHD involvement and only in 7.4% of cases failed to identify this disease, a retosigmoidoscopy may be an effective procedure for GI-GVHD diagnosis. However, CMV infection may be underdiagnosed with this approach. Introduction: Autologous graft versus host disease (autoGVHD) is a recently recognized, rare transplant complication with significant morbidity and mortality. Pathogenesis and risk factors for autoGVHD are poorly understood. We hypothesized that patients with multiple myeloma might be predisposed to autoGVHD through disregulation of immune response resulting from their treatment with immunomodulatory agents (IMiDs) and chemotherapeutic mobilization regimens. Patients and Methods: We identified 8 patients with multiple myeloma treated between 2005-2013 with biopsyproven autoGVHD after transplant. We identified 2 nonautoGVHD controls per autoGVHD patient matched by the time of hematopoietic progenitor cell (HPC) collection (within 15 days). Reference samples from HPC products of autoGVHD, non-autoGVHD myeloma patients, and 7 healthy controls were thawed and examined for cell surface marker expression of CD3, CD4, CD8, CD25, and CD56 and intracellular expression of FoxP3 by multicolor flow cytometry. Information on the following variables was collected: number of transplants prior to developing autoGVHD, mobilization regimens, exposure to a proteosome inhibitor, bortezomib, and IMiDs (thalidomide, lenalidomide and pomalidomide), and human leukocyte class I antigens (HLA A and B). Results: Myeloma patients with and without autoGVHD were well matched for age (60 AE 5.3 and 62.1 AE 7.8 years) and sex (50% and 43.8% male). Regulatory T-cells were decreased, but not significantly, in patients with autoGVHD (1.6 AE 1.4%) compared to non-autoGVHD patients (2.1 AE 1.7%).There was no difference in the NK cell population in the 2 groups. CD3 + cell percentage was significantly lower in autoGVHD (46.6 AE 12.4%) than the non-autoGVHD patients (59.1 AE 14.4%, p ¼ 0.047). On subset analysis of CD3 + cells, CD8 + cells were found to be significantly lower in patients with autoGVHD 
